Pharmaceuticals

Filgrastim Biosimilars Market Forecast: How Big Will It Be by 2030?

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the filgrastim biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Filgrastim Biosimilars Market?

The filgrastim biosimilars market size has seen rapid expansion in recent years. It is anticipated to expand from $1.19 billion in 2025 to $1.33 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.5%. Historically, this growth can be ascribed to the elevated cost of originator filgrastim, the increasing occurrence of cancer and blood disorders, restricted access to biologics in developing regions, advancing hospital infrastructure, and prompt approvals of biosimilars by regulatory bodies.

The filgrastim biosimilars market is anticipated to undergo significant expansion in the coming years, with its valuation projected to reach $2.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This projected growth during the forecast period is primarily driven by the introduction of next-generation filgrastim biosimilars, the expansion of contract manufacturing alliances, increased adoption in chronic and autoimmune diseases, growing government backing and reimbursement policies, and the development of patient-centric distribution and delivery models. Important trends for this period include the rising acceptance of filgrastim biosimilars in oncology and blood disorder treatments, the proliferation of contract manufacturing organizations for biosimilar production, an increased reliance on in-house vertically integrated manufacturing facilities, a developing preference for hospital and retail pharmacy distribution channels, and a focus on cost-effective biologics and improved access in emerging markets.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Drivers Are Supporting Technological Adoption In The Filgrastim Biosimilars Market?

An escalating incidence of cancer is anticipated to fuel the expansion of the filgrastim biosimilars market moving forward. Cancer describes a collection of diseases distinguished by the unregulated multiplication and dissemination of abnormal cells within the body, triggered by genetic alterations that interfere with normal cellular regulation. The increase in cancer cases is partially attributed to an aging global population, as individuals living longer face a higher probability of acquiring genetic mutations that contribute to cancer development. Filgrastim biosimilars provide support to cancer patients by stimulating white blood cell production, thereby reducing the danger of neutropenia induced by chemotherapy and enabling safer, more consistent cancer treatment. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, averaging 972 per day, which signifies an increase of 8,605 compared to 2022. Hence, the increasing occurrence of cancer is a key driver for the filgrastim biosimilars market.

What Segment Types Are Examined In The Filgrastim Biosimilars Market?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Which Trends Are Expected To Influence The Filgrastim Biosimilars Market In The Upcoming Years?

Leading companies in the filgrastim biosimilar market are innovating products with advanced methods like recombinant DNA technology for biosimilar creation. Recombinant DNA technology is a procedure where hybrid or chimeric DNA is formed by inserting a foreign sequence into an organism’s DNA. For example, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, introduced FYLNETRA (pegfilgrastim-pbbk) in the United States. This biosimilar to Amgen’s NEULASTA is prescribed for addressing and preventing febrile neutropenia. It encourages the proliferation and differentiation of neutrophils from specific precursor cells, prompts their development, and boosts the vitality and functionality of mature neutrophils, thereby causing dose-dependent increases in neutrophil counts. The release of Fylnetra contributes to a new phase of accessible medicines and expands availability for patients, healthcare providers, and payors.

Who Are The Prominent Global Companies Shaping The Filgrastim Biosimilars Market Landscape?

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Filgrastim Biosimilars Market?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Filgrastim Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=4016&type=smp

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2026, By The Business Research Company

Neutropenia Biologic Drug Treatments Market Report 2026

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

G Csf Market Report 2026

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Pegfilgrastim Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795